A multi-center randomized, parallel-group, double-blind, placebo-controlled study of XP19986 in subjects with symptomatic gastroesophageal reflux disease (GERD)

Trial Profile

A multi-center randomized, parallel-group, double-blind, placebo-controlled study of XP19986 in subjects with symptomatic gastroesophageal reflux disease (GERD)

Completed
Phase of Trial: Phase II

Latest Information Update: 25 Sep 2016

At a glance

  • Drugs Arbaclofen placarbil (Primary)
  • Indications Gastro-oesophageal reflux; Heartburn
  • Focus Therapeutic Use
  • Sponsors XenoPort
  • Most Recent Events

    • 26 Apr 2011 Results published in the American Journal of Gastroenterology.
    • 27 Oct 2010 Safety results were presented at the 18th United European Gastroenterology Week.
    • 05 May 2010 Pharmacokinetic/pharmacodynamic results have been presented at Digestive Disease Week (DDW) 2010.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top